Brokerage firm H.C. Wainwright Downgrades its rating on Juniper Pharmaceuticals Inc(NASDAQ:JNP). The shares have been rated Neutral. Previously, the analysts had a Buy rating on the shares. The rating by H.C. Wainwright was issued on Aug 19, 2016.
In a different note, On Aug 18, 2016, Northland Securities said it Downgrades its rating on Juniper Pharmaceuticals Inc. The shares have been rated ‘Market Perform’ by the firm.
Juniper Pharmaceuticals Inc (JNP) made into the market gainers list on Mondays trading session with the shares advancing 0.70% or 0.04 points. Due to strong positive momentum, the stock ended at $5.75, which is also near the day’s high of $5.75. The stock began the session at $5.66 and the volume stood at 12,116 shares. The 52-week high of the shares is $15.44 and the 52 week low is $4.3. The company has a current market capitalization of $62 M and it has 1,08,43,752 shares in outstanding.
Juniper Pharmaceuticals Inc(JNP) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $11.88M. Analysts had an estimated revenue of $9.49M. Earnings per share were $-0.16. Analysts had estimated an EPS of $-0.08.
Several Insider Transactions has been reported to the SEC. On Dec 8, 2015, C Ann Merrifield (director) purchased 1,600 shares at $12.14 per share price.Also, On Nov 20, 2015, Nikin Patel (COO) purchased 5,000 shares at $11.67 per share price.On Nov 19, 2015, James A Geraghty (director) purchased 8,000 shares at $11.75 per share price, according to the Form-4 filing with the securities and exchange commission.
Juniper Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women’s health. Juniper develops pharmaceutical products including CRINONE 8% (progesterone gel) which is marketed by Allergan Inc. in the United States and by Merck KGaA Darmstadt Germany in over 90 countries worldwide. The Company has in-house pharmaceutical development clinical trial manufacturing and analytical capabilities to advance its internal development pipeline including a 10% lidocaine bioadhesive vaginal gel in Phase IIb for gynecologic procedure-related pain and intra-vaginal rings for overactive bladder HRT and prevention of preterm birth while also providing consultative services to its pharmaceutical industry customers. Juniper Pharmaceuticals and Juniper Pharma Services are trademarks of the Company in the United States and European Union. CRINONE is a trademark of Allergan Inc. in the United States.